Aquestive Therapeutics (AQST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AQST · Stock Price

USD 4.23+1.44 (+51.61%)

Market Cap: $528.8M

Historical price data

Market Cap: $528.8MPipeline: 10 drugs (1 Phase 3)Patents: 20Founded: 2006HQ: Warren, United States

Sector Ranking#65 in Drug Delivery & Formulation

Overview

Aquestive Therapeutics is a mission-driven company focused on simplifying complex drug delivery to meaningfully improve patient lives. Its core achievement is establishing the PharmFilm® oral film platform as a global standard, with over 2 billion doses delivered across six continents and a robust IP portfolio of over 200 patents. The company's strategy combines advancing a late-stage proprietary pipeline for severe allergies and epilepsy with a profitable CDMO and licensing business that provides revenue and validates the technology. This dual approach aims to drive sustainable growth by addressing significant unmet needs in rescue medication and neurological care.

CNS ConditionsSevere Allergies

Technology Platform

Proprietary PharmFilm® oral film technology for rapid transmucosal (buccal/sublingual) drug delivery, enabling fast onset of action, enhanced bioavailability, and patient-friendly administration.

Pipeline

10

10 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg w...	Epilepsy	Phase 3
Riluzole Oral Soluble film (ROSF) 50 mg	Amyotrophic Lateral Sclerosis	Phase 2
Diazepam Buccal Film	Epilepsy	Phase 2
Diazepam Buccal Film 12.5 mg	Epilepsy	Phase 2
Riluzole Oral Soluble Film	ALS	Phase 2

FDA Approved Drugs

1

SYMPAZANNDANov 1, 2018

Opportunities

The primary opportunity is disrupting the multi-billion dollar epinephrine auto-injector market with Anaphylm™, a needle-free, convenient alternative that could improve patient compliance and expand market access.

Additionally, the PharmFilm® CDMO platform is well-positioned to capitalize on the growing demand from pharma companies for innovative drug delivery solutions to enhance or rescue drug assets.

Risk Factors

Key risks include clinical/regulatory failure of lead asset Anaphylm™, commercial execution challenges against entrenched competitors in the anaphylaxis market, and potential future dilution as the company funds its late-stage development and launch preparations.

Competitive Landscape

Aquestive is the dominant leader in oral film delivery with unmatched scale and IP. In its target indications, it faces competition from auto-injector giants (e.g., Viatris) in anaphylaxis and other benzodiazepine formulations in epilepsy. Its core advantage is its versatile platform, which allows it to compete across multiple therapeutic areas and business models.